Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Carcinoma, Nonsquamous Non-small-cell Lung Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Cisplatin, Necitumumab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Nyack, New York

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions: inupadenant, Placebo, Carboplatin, Pemetrexed; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Tampa, Florida

Conditions: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions: ladiratuzumab vedotin, pembrolizumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 27
States / cities: Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more

Conditions: Nonsquamous Non-small Cell Lung Cancer
Interventions: Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed; Combination Product
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Glendale, Arizona • Norwich, Connecticut • Fredericksburg, Virginia

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Fort Myers, Florida • Miami, Florida + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: paclitaxel + carboplatin + bevacizumab, carboplatin + paclitaxel + bevacizumab + PF-3512676; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 29
States / cities: Bessemer, Alabama • Birmingham, Alabama • Mobile, Alabama + 17 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Docetaxel, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 12 more

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, pemetrexed disodium; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 70 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 217
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 140 more

Conditions: Non Small Cell Lung Cancer
Interventions: eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Fort Myers, Florida + 3 more

Conditions: Non Small Cell Lung Cancer
Interventions: Liquid biopsy; Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 9
States / cities: Birmingham, Alabama • Stamford, Connecticut • Miami Beach, Florida + 6 more

Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung, Nonsmall Cell Lung Cancer Stage III
Interventions: Pemetrexed, Carboplatin, Radiation Therapy, Cisplatin, Lobectomy; Drug · Radiation · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Sotorasib, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 21
States / cities: Santa Barbara, California • Newark, Delaware • Chicago, Illinois + 16 more

Search by objective public record fields.

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Cisplatin and Pemetrexed With Radiation Followed by Lobectomy

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)